Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer[1].
Molecular Weight:
(145.28 kDa)
Purity:
99.96
CAS Number:
[2250342-36-8]
Target:
VEGFR
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted